• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Synergy CHC Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    6/4/25 8:37:50 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care
    Get the next $SNYR alert in real time by email
    false 0001562733 0001562733 2025-05-30 2025-05-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 30, 2025

     

    SYNERGY CHC CORP.

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-42374   99-0379440
    (State or Other Jurisdiction   (Commission File Number)   (IRS Employer
    of Incorporation)       Identification No.)

     

    865 Spring Street, Westbrook, Maine   04092
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (902) 237-1220

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   SNYR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On May 30, 2025, Synergy CHC Corp. (the “Company”) entered into a term loan credit agreement (the “Credit Agreement”) with ACP Agency, LLC (“ACP”). The Credit Agreement consists of a $15.0 million term loan (the “Term Loan”), up to $2.5 million in a committed delayed draw facility (the “Delayed Draw Facility”), and up to $2.5 million in an uncommitted term loan incremental facility (the “Incremental Facility”), which facilities are secured by all of the assets of the Company and certain of its subsidiaries; including, without limitation, a pledge of the Company’s equity interests in its subsidiaries and their respective rights to intellectual property. Further, the obligations of the Company under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries. The proceeds of the Term Loan are to be used to repay existing indebtedness of the Company, pay related fees and transaction costs, and provide working capital to the Company. The proceeds of the Delayed Draw Facility are to be used to pay off all indebtedness owed by the Company pursuant to certain settlement agreements. All capitalized words used but not defined herein have the meanings assigned in the Credit Agreement.

     

    The Credit Agreement has customary representations, warranties and covenants including restrictions on indebtedness, liens, restricted payments and dividends, investments, asset sales and similar covenants and contains customary events of default. The Credit Agreement also contains covenants requiring the Company and its subsidiaries to maintain a maximum (x) consolidated senior net leverage ratio of (i) 3.25:1.00 for the quarter ending September 30, 2025, (ii) 3.25:1.00 for the quarter ending December 31, 2025, (iii) 3.00:1.00 for the quarter ending March 31, 2026, (iv) 2.75:1.00 for the quarter ending June 30, 2026, (v) 2.75:1.00 for the quarter ending September 30, 2026, and (vi) 2.50:1.00 for the quarter ending December 31, 2026 and each fiscal quarter ended thereafter and (y) a fixed charge coverage ratio of 1.20 for the quarter ending September 30, 2025 and each fiscal quarter ended thereafter.

     

    Of the Term Loan, $175,000 is subject to repayment on each of January 1, 2026, April 1, 2026, July 1, 2026 and October 1, 2026 and the remaining balance is to be repaid in the amount of $350,000 beginning January 1, 2027 and the first day of each quarter thereafter. The Term Loan bears interest at a rate equal to the Term SOFR rate plus 8.50%. The Delayed Draw Facility and Incremental Facility, if applicable, shall bear interest following any advance of proceed thereunder, at a rate of either (x) (i) Term SOFR rate plus (ii) 8.5%, or (y) (i) a reference rate equal to the greater of (a) 6.0% per annum, (b) the federal funds rate plus 0.50% per annum, (c) the Term SOFR rate plus 1% per annum, and (d) the rate last quoted by The Wall Street Journal as the “Prime Rate” in the United States, plus (ii) 7.50%.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

     

    The information under Item 1.01 of this Form 8-K is incorporated by reference into this Item 2.03.

     

    Item 8.01 Other Events.

     

    On June 4, 2025, the Company issued a press release regarding the closing of the Credit Agreement. A copy of the press release is attached as Exhibit 99.1 hereto.

     

    Item 9.01 Financial Statements and Exhibits.‌

     

    (d) Exhibits

     

    Exhibit No.   Description
    10.1 ¥   Credit Agreement, dated as of May 30, 2025, by and among Synergy CHC Corp. as Borrower, each subsidiary of the Borrower listed as a Guarantor therein, the lenders from time-to-time party thereto as Lenders and ACP Agency, LLC, as Collateral Agent and Administrative Agent.
    99.1   Press Release, dated June 4, 2025
    104   Cover Page Interactive Data File (embedded within the inline XBRL document)

     

    ¥Certain schedules and exhibits to this agreement have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC on request.

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 4, 2025  
       
      SYNERGY CHC CORP.
         
      By: /s/ Jack Ross
      Name:  Jack Ross
      Title: Chief Executive Officer

     

     

    2

     

     

    Get the next $SNYR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNYR

    DatePrice TargetRatingAnalyst
    1/21/2025$10.00Buy
    ROTH MKM
    More analyst ratings

    $SNYR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Synergy CHC Announces New $20 Million Long-Term Credit Facility

      WESTBROOK, Maine, June 04, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that it has entered into a $20 million term loan credit agreement, due May 2029 with ACP Agency, LLC. The proceeds will be used to pay down debt and provide the Company with growth capital. Under the terms of the agreement, the Company received a $15 million term loan at closing, with an interest rate of SOFR plus 8.5%. The loan is interest-only through 2025, with quarterly principal payments of $175,000 beginning in January 2026, increasing to $350,000 per quarter in 2027 and beyond. A $2.5 million de

      6/4/25 8:30:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

      WESTBROOK, Maine, May 29, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that Erik Shields has been named Vice President of Beverage of Synergy, effective May 26, 2025. "We're excited to welcome Erik to the team and look forward to his contributions," said Jack Ross, CEO of Synergy. "With nearly two decades of experience leading national strategies, managing key accounts, and building high-performance teams, Erik brings the leadership and executional expertise needed to help scale our beverage business. As we focus on accelerating growth in this category, we're confident he w

      5/29/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of Profitability

      WESTBROOK, Maine, May 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025. "We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in the prior year period. This performance highlights the strength of our operating model and our ongoing discipline around cost management." "We continue to make meaningful progress toward

      5/15/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Synergy CHC Corp.

      SC 13D - Synergy CHC Corp. (0001562733) (Subject)

      10/31/24 9:55:58 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Synergy CHC Corp.

      SC 13G - Synergy CHC Corp. (0001562733) (Subject)

      10/25/24 7:46:44 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 5:05:31 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $39,350 worth of shares (14,340 units at $2.74), increasing direct ownership by 4% to 361,207 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 4:46:18 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $59,521 worth of shares (15,200 units at $3.92), increasing direct ownership by 5% to 346,877 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      3/3/25 9:25:39 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 5:05:31 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $39,350 worth of shares (14,340 units at $2.74), increasing direct ownership by 4% to 361,207 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 4:46:18 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $59,521 worth of shares (15,200 units at $3.92), increasing direct ownership by 5% to 346,877 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      3/3/25 9:25:39 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Synergy CHC Corp. with a new price target

      ROTH MKM initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $10.00

      1/21/25 9:10:17 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Financials

    Live finance-specific insights

    See more
    • Synergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of Profitability

      WESTBROOK, Maine, May 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025. "We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in the prior year period. This performance highlights the strength of our operating model and our ongoing discipline around cost management." "We continue to make meaningful progress toward

      5/15/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call Information

      WESTBROOK, Maine, May 01, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that it plans to release financial results for the first quarter ended March 31, 2025, on Thursday, May 15, 2025, before the open of market trading. In conjunction with reporting first quarter 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's website. To access the call by

      5/1/25 4:05:00 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call Information

      WESTBROOK, Maine, March 20, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that it plans to release financial results for the fourth quarter and full year ended December 31, 2024, on Monday, March 31, 2025, before the open of market trading. In conjunction with reporting fourth quarter and full year 2024 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Syner

      3/20/25 4:05:00 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Leadership Updates

    Live Leadership Updates

    See more
    • Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

      WESTBROOK, Maine, May 29, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that Erik Shields has been named Vice President of Beverage of Synergy, effective May 26, 2025. "We're excited to welcome Erik to the team and look forward to his contributions," said Jack Ross, CEO of Synergy. "With nearly two decades of experience leading national strategies, managing key accounts, and building high-performance teams, Erik brings the leadership and executional expertise needed to help scale our beverage business. As we focus on accelerating growth in this category, we're confident he w

      5/29/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    SEC Filings

    See more
    • Synergy CHC Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - Synergy CHC Corp. (0001562733) (Filer)

      6/4/25 8:37:50 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-Q filed by Synergy CHC Corp.

      10-Q - Synergy CHC Corp. (0001562733) (Filer)

      5/15/25 8:05:55 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Synergy CHC Corp. (0001562733) (Filer)

      5/15/25 8:00:17 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care